Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Plus Ziv-Aflibercept in Metastatic Uveal Melanoma
NCT06121180Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2024
- Primary completion
- Oct 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and aflibercept in Uveal melanoma (UM) and melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 5 years. Started Nov 2024; status: recruiting.
02
Drugs
cemiplimabaflibercept
03
Conditions
Uveal melanoma (UM)melanoma
Beyond the preview
Go deeper on NCT06121180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121180.